An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Study found that epoprostenol, iloprost, bosentan, sitaxentan and sildenafil, when added to supportive treatment and used at licensed dose(s), were more effective than supportive treatment alone for the treatment of adults with pulmonary arterial hypertension. The cost-effectiveness of drugs used to treat functional class III patients depends partly on the treatment available in functional class IV and its costs. The only drug currently licensed for functional class IV (epoprostenol) may not be cost-effective by currently used thresholds
1 Public Health, Epidemiology & Biostatistics, School of Health & Population Sciences, University of Birmingham, , UK
2 Health Economics, School of Health & Population Sciences, University of Birmingham, , UK
3 Imperial College London and Hammersmith Hospital, London, UK
4 Papworth Hospital, Papworth Everard, Cambridge, UK
* Corresponding author Email:
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document